Algernon Pharmaceuticals Inc (AGNPF)

[Money $hot]

The Outside Man Looking For The Inside Man

My best guess is delusion and dilution will be synonymous to the Algernon story for the foreseeable future. In Christopher Moreau's (CEO) case he takes the cake with Delusions of Grandeur.

As it all relates to this msg board...here we go AGAIN!

Yo tcm55, I get where you're coming from but unfortunately it doesn't mean jack shit as it relates to the COVID-19 study having been a complete flop.

Are you aware of the fact that Interleukin 6 (IL-6) was not...I repeat WAS NOT a Primary or Secondary Outcome (Endpoint) of the COVID-19 study.

https://clinicaltrials.gov/ct2/show/NCT04382924

My Commentary: What you have with Interleukin 6 (IL-6) is after the fact bullshit. If it meant anything of actual significance for the COVID study Moreau wouldn't have finally surrendered to his lame ass narrative about approaching the FDA to move to Phase 3.

Furthermore, Andre Uddin also would have pointed out any statistical significance to his clients that cling to his every word. Thus, it would appear that the only two people who believed in a chance in hell for COVID-19 at Phase 3 is you and Moreau. The overall market responded harshly and rightfully so to Topline data and the stock has never recovered since.

News Release - "Algernon Pharmaceuticals has reported that NP-120 (Ifenprodil) statistical significantly lowered interleukin 6 (IL-6) in its Phase IIb/III trial to treat Covid-19."

^Interleukin 6...Guess What...Nobody Cares.
________________

Article Regarding Andre Uddin: In an update to clients on Wednesday, Uddin moved AGN from a “Speculative Buy” to a “Hold,” saying investors should now be focusing on Algernon’s data for its idiopathic pulmonary fibrosis trial, due in the second half of 2021.

Ifenprodil missed the primary endpoint by showing no difference from the control group, while on all-cause mortality, the drug showed a very small non-significant improvement compared to the control group. On oxygenation, 100 per cent of patients with low blood oxygen on Ifenprodil returned to normal oxygen levels at Day 4 compared to Day 9 for patients in the control group, and on time in ICU, patients on the drug spent significantly less time in the ICU than those in the control group.

Commenting on the results, Uddin wrote, “The lack of a dose-dependent effect in a clinical trial normally suggests poor efficacy of a compound. AGN disclosed 40 mg ifenprodil did not show any effects in this study while the 20 mg dose demonstrated some trends. Based on the lack of dose response, we unfortunately would not expect this indication to be advanced.”

“Ifenprodil is in a Phase 2a trial in IPF/chronic cough where results are expected in H2 2021, and AGN’s DMT (a repurposed psychedelic compound) is expected to enter into a Phase 1 trial in stroke in H2 2021,” Uddin wrote. “Investors should re-focus their attention towards the IPF/cough data expected in H2 ’21.”

“Investors should note our AGN valuation is based on the IPF and chronic cough indications of ifenprodil – we are currently keeping our financial assumptions for the two indications intact in our model. We never assumed any revenues from ifenprodil’s COVID-19 indication,” he said.

Along with the new “Hold” rating, Uddin has cut his price target from $0.80 to $0.25, saying the drop is due to a decrease in assumed success rate for Ifenprodil. At the time of publication, the new target represented a projected one-year return of negative 15 per cent.

https://www.cantechletter.com/2021/04/take-a-pass-on-algernon-pharmaceuticals-says-mackie/#
________________

My Commentary:

Uddin's Hold rating of $0.25 is $0.20 USD (20 Cents per share). That's before the very harsh 100 to 1 reverse split. So Uddin's Hold rating would now represent a $20 USD share price at 1.68M Outstanding Shares. That's a Market Cap of $33.6M USD. Also, Uddin expected IPF/Chronic Cough data a year ago! Given the pending dilution and the crazy timeline to data there is no way Uddin still stands by that analysis. However, it appears that Algernon has cozied up to Uddin based on the Corporate Presentation having a banner with Andre Uddin as it's inhouse stock analyst. If anyone is getting word from Uddin about Algernon moving forward it likely would come in the same way the BioPub Dr. KSS looks out for his personal subscribers who pays him money for information. Algernon liked to wrap itself around people whose primary goal is to look out for everyone except common shareholders. Without an inside man you hold a shitty hand.

At the time of Uddin's analysis his projected 1 year return was negative 15 percent (15%).

To date, the return is in fact negative 78 percent (78%).

In reverse split adjustment terms since Uddin's analysis - the stock has dropped from $20 USD to $4.23 USD.

Pending dilution and the NASDAQ uplist will further wipe pre split shares off the map for the foreseeable future.

Ur On The Outside Looking In



As it relates to the Lockout in Australia...it speaks to the border. It does not speak to a Lock-down of it's residents like in China. Don't get the two twisted up in some cockamamie idea that their both one and the same. The bottom-line remains that Australia has a small population pool of potential clinical trial participants. That includes New Zealand where Algernon also remained stymied with dismal enrollment. Yet, the plan for Algernon is to go back to Australia for another slow rolled study of IPF and/or Chronic Cough. How wack is that?! V E R Y

Hav @ it

M$